Abstract 1787P
Background
The potential for PSMA PET-directed treatment decisions to improve outcomes in mHSPC remains unknown. We explored first response and progression/relapse patterns in newly diagnosed PSMA PET-detected mHSPC and correlated PET-directed staging with clinical outcomes.
Methods
184 patients with baseline PSMA PET were retrospectively reviewed. Patients were sub-grouped into oligometastatic disease (OMD) and polymetastatic disease (PMD) utilising the STAMPEDE2 trial definition. Data on patient demographics, treatment, and imaging findings were collected. Treatment response was assessed using PSA nadir and radiological imaging at six months from PSA nadir. Disease progression/relapse was assessed using PCWG3, RECIST 1.1 and PERCIST 1.0 criteria. Kaplan Meier method estimated median time to radiographic progression-free survival (rPFS).
Results
Median age was 69 years. All patients had androgen deprivation therapy. 161/184 (88%) had additional systemic therapies. 99/184 (54%) had OMD and 85/184 (46%) had PMD. Prostate radiotherapy was given in 76/99 (77%) OMD patients and 47/85 (55%) PMD patients. Median time to PSA nadir in OMD and PMD was 10 months (range 1 to 29) and 8 months (range 1 to 36), respectively. Response images were available in 35/99 (35%) OMD patients and 39/85 (46%) PMD patients. Median time to radiological response in OMD and PMD was 10 months (range 2 to 58) and 9 months (range 2 to 36), respectively. Radiological progression in OMD most frequently occurred with new sites of disease (73%). Median rPFS was 53 months (95% CI 40, undefined) in OMD patients and 35 months (95% CI 22, 43) in PMD patients. Table: 1787P
Radiological response and progression/relapse in OMD and PMD
OMD (N= 99) | PMD (N= 85) | |
Radiological response | n= 35 (35%) | n= 39 (46%) |
Complete Response | 12 (34%) | 7 (18%) |
Partial Response | 21 (60%) | 29 (74%) |
Stable Disease | 1 (3%) | 2 (5%) |
Not evaluable | 1 (3%) | 1 (3%) |
Site of Radiological progression/relapse compared with baseline disease | n= 22 (22%) | n= 37 (43%) |
Same sites | 5 (23%) | 18 (49%) |
Different sites | 10 (45%) | 9 (24%) |
Mixed sites | 6 (27%) | 10 (27%) |
Not evaluable | 1 (5%) | 0 (0%) |
Conclusions
PSMA PET-guided outcomes were similar to series with conventional staging, suggesting PET-directed therapy choices might not significantly influence time to progression. This will be further investigated in the forthcoming STAMPEDE2 trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Abdel-Aty.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1239P - NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Presenter: Charles Swanton
Session: Poster session 14
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14